Phenytoin: An anti-bipolar anticonvulsant?

International Journal of Neuropsychopharmacology

Volumn 9, Issue 4, 2006, Pages 479-484

  Bersudsky, Yuly ^a,b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b MENTAL HEALTH CENTER   (Israel)

Author keywords

Antidepressant; Controlled trial; Mania; Phenytoin; Prophylaxis

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; PHENYTOIN; PLACEBO; SODIUM CHANNEL BLOCKING AGENT; VALPROIC ACID;

ADD ON THERAPY; BIPOLAR DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; CROSSOVER PROCEDURE; DIZZINESS; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MANIA; MUSCLE WEAKNESS; PRIORITY JOURNAL; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SOMNOLENCE; SURVIVAL;

ANTICONVULSANTS; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; HUMANS; PHENYTOIN;

EID: 33745538373     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145705006140     Document Type: Review

References (34)

1. Bersudsky Y, Winokur M, Mishory A (2003). Prophylactic effects of phenytoin in bipolar illness. Bipolar Disorders 5, 464-467.
2. Boelhouwer C, Henry CE, Glueck Jr. BC (1968). Positive spiking: a double-blind control study on its significance in behavior disorders, both diagnostically and therapeutically. American Journal of Psychiatry 125, 473-481.
3. Bowden C, Calabrese J, McElroy S, Gyulai L, Wassef A, Petty F, Pope Jr. HG, Chou JC, Keck Jr. PE, Rhodes L, Swann A, Hirschfeld R, Wozniak P (2000). A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Archives of General Psychiatry 57, 481-489.
4. Bowden C, Calabrese J, Sachs G, Yatham L, Asghar S, Hompland M, Montgomery P, Earl N, Smoot T, DeVeaugh-Geiss J, and Lamictal 606 Study Group (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry 60, 392-400.
5. Bowden CL (2001). Novel treatments for bipolar disorder. Expert Opinion on Investigative Drugs 10, 661-671.
6. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD (1999). A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry 60, 79-88.
7. Case WG, Rickels K, Bazilian S (1969). Diphenylhydantoin in neurotic anxiety. American Journal of Psychiatry 126, 254-255.
8. Cox DR (1964). Some applications of exponential ordered scores. Journal of the Royal Statistical Society 26, 103-110.
9. Davis LL, Kabel D, Patel D, Choate AD, Foslien-Nash C, Gurguis GN, Kramer GL, Petty F (1996). Valproate as an antidepressant in major depressive disorder. Psychopharmacological Bulletin 32, 647-652.
10. Devinsky O (1995). Cognitive and behavioral effects of antiepileptic drugs. Epilepsia 32 (Suppl. 2), S46-65.
11. Dichter MA (1998). Mechanisms of action of new antiepileptic drugs. Advances in Neurology 76, 1-9.
12. Garattini S, Bertele V, Li Bassi L (2003). How can research committees protect patients better? British Medical Journal 326, 1199-1201.
13. Guy W (1976). Assessment Manual for Psychopharmacology. US Dept of Health, Education and Welfare publication, 218-222.
14. Hamilton M (1960). A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 23, 56-62.
15. Jonas AD (1967). The diagnostic and therapeutic use of diphenylhydantoin in the subictal state and non-epileptic dysphoria. International Journal of Neuropsychiatry 3 (Suppl. 2), 21-29.
16. Kalinowsky LB, Putnam TJ (1943). Attempts at treatment of schizophrenia and other non-epileptic psychoses with Dilantin. Archives of Neurological Psychiatry 49, 414-420.
17. Lee ET (1980). Statistical Methods for Survival Data Analysis. Belmont, CA: Lifetime Learning.
18. Levine J, Bersudsky Y, Nadri C, Yaroslavsky Y, Abed N, Mishory A, Agam G, Belmaker R (2003). Mechanism of action of new mood stabilizing drugs. In : Soares J, Gershon S (Eds.), Handbook of Medical Psychiatry (pp. 793-807). New York: Marcel Dekker.
19. Macdonald RL, Kelly KM (1995). Antiepileptic drug mechanisms of action. Epilepsia 36 (Suppl. 2), S2-12.
20. Mishory A, Yaroslavsky Y, Bersudsky Y, Belmaker RH (2000). Phenytoin as an antimanic anticonvulsant: a controlled study. American Journal of Psychiatry 157, 463-465.
21. Mitchell PB, Malhi GS (2002). The expanding pharmacopoeia for bipolar disorder. Annual Review of Medicine 53, 173-188.
22. Nemets B, Bersudsky Y, Belmaker RH (2005). Controlled double-blind trial of phenytoin vs. fluoxetine in major depressive disorder. Journal of Clinical Psychiatry 66, 586-590.
23. Neumann J, Seidel K, Wunderlich HP (1984). Comparative studies of the effect of carbamazepine and trimipramine in depression. In: Einrich HM, Okuma T, Muller AA (Eds.), Anticonvulsants in Affective Disorders (pp. 160-166). Amsterdam: Elsevier Science Publishing.
24. Overall J, Gorham D (1962). The brief psychiatric rating scale. Psychological Reports 10, 799-812.
25. Petty F, Davis AL, Nugent M, Bollig M, Hendricks KR (1999). Valproate treatment of bipolar depression. 54th Annual Convention Society of Biological Psychiatry 45, p. 71S, Washington.
26. Post RM (1989). Use of anticonvulsants in the treatment of manic-depressive illness. In: Post RM, Trimble MR, Pippenger CE (Eds.), Clinical Use of Anticonvulsants in Psychiatric Disorders (pp. 113-152). New York: Demos Publications.
27. Post RM, Uhde TW, Roy-Byrne PP, Joffe RT (1986). Antidepressant effects of carbamazepine. American Journal of Psychiatry 143, 29-34.
28. Sachs GS (1996). Treatment-resistant bipolar depression. Psychiatric Clinics of North America 19, 215-236.
29. Schaff MR, Fawcett J, Zajecka JM (1993). Divalproex sodium in the treatment of refractory affective disorders. Journal of Clinical Psychiatry 54, 380-384.
30. Small JG (1990). Anticonvulsants in affective disorders. Psychopharmacology Bulletin 26, 25-36.
31. Steinacher L, Vandel P, Zullino DF, Eap CB, Brawand-Amey M, Baumann P (2002). Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study. European Neuropsychopharmacology 12, 255-260.
32. Turner WJ (1967). The usefulness of diphenylhydantoin in treatment of non-epileptic emotional disorders. International Journal of Neuropsychiatry 3 (Suppl. 2), 8-20.
33. Winsberg ME, DeGolia SG, Strong CM, Ketter TA (2001). Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. Journal of Affective Disorders 67, 207-212.
34. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978). A rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry 133, 429-435.